VIVUS, Inc. (NASDAQ:VVUS)’s share price was down 16.1% during trading on Monday . The company traded as low as $0.47 and last traded at $0.47. Approximately 1,290,850 shares changed hands during mid-day trading, an increase of 51% from the average daily volume of 853,673 shares. The stock had previously closed at $0.56.

A number of equities analysts have recently commented on VVUS shares. Zacks Investment Research raised shares of VIVUS from a “sell” rating to a “hold” rating in a research report on Thursday. ValuEngine raised shares of VIVUS from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd.

The company has a market capitalization of $59.49 million, a PE ratio of -1.62 and a beta of 0.46. The company has a current ratio of 4.93, a quick ratio of 4.26 and a debt-to-equity ratio of -10.60.

VIVUS (NASDAQ:VVUS) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The company had revenue of $14.96 million during the quarter. VIVUS had a negative return on equity of 843.43% and a negative net margin of 72.78%. equities research analysts forecast that VIVUS, Inc. will post -0.44 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in VIVUS stock. Renaissance Technologies LLC lifted its stake in VIVUS, Inc. (NASDAQ:VVUS) by 5.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,273,800 shares of the biopharmaceutical company’s stock after acquiring an additional 423,100 shares during the period. Renaissance Technologies LLC owned approximately 7.79% of VIVUS worth $5,833,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 17.86% of the company’s stock.


VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

Further Reading: Stop Order Uses For Individual Investors

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with's FREE daily email newsletter.